利培酮和氯丙嗪分别合并碳酸锂治疗双相障碍躁狂发作120例的对照研究  

A comparative study of Risperidone versus Chlorpromazine combined with lithium carbonate in treatment with bipolar disorder manic episodes

作　　者：胡林云 崔明[1] 宋红梅[1] 韩从社 李祥[1] 

机构地区：[1]安徽省荣军医院,安徽怀远233400

出　　处：《中国民康医学》2013年第7期26-28,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:比较利培酮和氯丙嗪分别合并碳酸锂治疗双相障碍躁狂发作的疗效和安全性。方法:将120例双相障碍躁狂发作的患者随机分为利培酮组(60例)和氯丙嗪组(60例),观察8周。在治疗前、治疗第1、2、4、8周末分别进行Bech-Rafaelsen躁狂量表(BRMS),不良反应症状量表(TESS)评定,和血尿常规、肝肾功能、血锂浓度及心电图等检查。结果:治疗8周末两组BRMS评分较治疗前显著减低(P<0.01),同期两组之间的BRMS评分差异无显著性(P﹥0.05)。利培酮组有效率90%,氯丙嗪组有效率85%,两组差异无显著性(P﹥0.05)。不良反应利培酮组较氯丙嗪组少而轻,差异明显(P<0.05)。结论:利培酮和氯丙嗪分别合并碳酸锂治疗双相障碍躁狂发作的疗效相当,但前者安全性高,不良反应少。Objective：To evaluate the efficacy and safety of Risperidone and chlorpromazine combined with lithium carbonate in treating patients with bipolar disorder manic episodes＇s nethods：120 patients with bipolar disorder manic episode were randomly di- vided into two groups treated with Risperidone （ n = 60） or chlorpromazine （ n = 60）. The patients were evaluated with Bech - Rafaelsen Mania Rating Scale, TESS before treatment and on 1st. 2rid. 4th and 8th weekend after treatment＇s Results： At the end of treatment, BRMS score was significantly reduce in two groups （P 〈 0.01 ）. Over the same period in two groups of BRMS score were not significant- ly. The clinical response rate were 90% in Risperidone group and 85% in chlorpromazine group . No significant difference between the two group. But the side effects of Risperidone group less than chlorpromazine group with significant differences between the two groups＇s Conclusions： The combination of risperidond and lithium carbonate has similar the therapeutic effect to chlorpromazine in the treatment of manic episindes, but Risperidone has superior safety and fewer side effects.

关 键 词：利培酮 氯丙嗪 碳酸锂 双相障碍 躁狂发作 

分 类 号：R749.41[医药卫生—神经病学与精神病学]